Company
|
Type
|
Founded
|
Number of employees
|
Average 10 years (2006–2016) revenue (M$)
|
Revenue per employee ($)
|
---|
Helsinn
|
NRDO
|
1976
|
680
|
320
|
470,588
|
Jazz Pharma
|
NRDO
|
2003
|
1040
|
615
|
591,346
|
Tesaro+
|
NRDO
|
2010
|
446
|
0.45
|
1010
|
Puma Biotech++
|
NRDO
|
2010
|
183
|
0
|
0
|
Clovis
|
NRDO
|
2009
|
278
|
0.14
|
504
|
Vanda Pharma
|
NRDO
|
2002
|
148
|
38
|
256,756
|
Debiopharm
|
NRDO
|
1979
|
150
|
345
|
2,300,000
|
Astra Zeneca
|
Large Pharma
|
1999
|
59,700
|
23,000
|
385,260
|
Novartis
|
Large Pharma
|
1996
|
12,3000
|
47,000
|
382,114
|
Sanofi
|
Large Pharma
|
2004
|
110,000
|
32,500
|
295,454
|
Eli Lilly
|
Large Pharma
|
1876
|
42,000
|
21,500
|
511,905
|
Bayer
|
Large Pharma
|
1863
|
115,000
|
43,000
|
373,913
|
Pfizer
|
Large Pharma
|
1849
|
96,500
|
51,000
|
528,497
|
GSK
|
Large Pharma
|
2000
|
99,300
|
26,400
|
345,619
|
Amgen
|
Large Biotech
|
1980
|
19,200
|
20,000
|
1,041,667
|
- NRDO ‘No Research, Development Only’ companies that do not conduct early research and have not chosen to conduct sell and market their own assets; + calculated over 6 years; ++ calculated over 7 years